Morgan Stanley analyst Drew Ranieri added SI-Bone (SIBN) as a Top Pick, stating that the firm is “encouraged” with SI-Bone’s multi-pronged growth story and ability to drive beats/raises, as well as what the firm sees as “a clearer pathway to adjusted EBITDA breakeven.” Within the firm’s SMID-cap MedTech coverage, Alphatec (ATEC) and ShockWave Medical (SWAV) both “still remain favorite names,” the analyst added. Morgan Stanley has an Overweight rating and $30 price target on SI-Bone shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SIBN:
- SI-Bone price target lowered to $31 from $33 at Truist
- SI-Bone raises FY23 revenue view to $132M-$134M from $128M-$131M
- SI-Bone reports Q2 EPS (30c), consensus (40c)
- SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance
- Si-Bone (SIBN) Q2 Earnings Cheat Sheet